1. Home
  2. RXO vs LQDA Comparison

RXO vs LQDA Comparison

Compare RXO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RXO Inc.

RXO

RXO Inc.

N/A

Current Price

$27.38

Market Cap

4.0B

Sector

N/A

ML Signal

N/A

LQDA

Liquidia Corporation

N/A

Current Price

$45.22

Market Cap

3.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RXO
LQDA
Founded
2022
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.8B
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
RXO
LQDA
Price
$27.38
$45.22
Analyst Decision
Hold
Buy
Analyst Count
18
8
Target Price
$27.96
★ $54.38
AVG Volume (30 Days)
★ 4.8M
4.7M
Earning Date
10-29-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 72.81
51.81
EPS
N/A
★ 1.26
Revenue
★ $5,742,000,000.00
$158,320,000.00
Revenue This Year
$21.78
$357.27
Revenue Next Year
$9.82
$1.34
P/E Ratio
★ N/A
$35.87
Revenue Growth
26.20
★ 1031.18
52 Week Low
$10.43
$22.31
52 Week High
$29.90
$93.61

Technical Indicators

Market Signals
Indicator
RXO
LQDA
Relative Strength Index (RSI) 55.24 51.26
Support Level $25.88 $35.00
Resistance Level $29.71 $46.67
Average True Range (ATR) 0.60 2.88
MACD -0.39 2.62
Stochastic Oscillator 3.55 89.61

Price Performance

Historical Comparison
RXO
LQDA

About RXO RXO Inc.

RXO Inc is a brokered transportation platform defined by technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: